Developer docs
API playgroundTry for free, no card

Search company profiles

Avectas

Full company profile

uuid0005f3i

Namestring
Avectas
Legal namestring
Avectas
Websiteurl
avectas.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Avectas is a privately held Irish cell engineering technology company headquartered in Maynooth, Ireland, with an additional R&D facility in Dublin and a North American commercial office in Cambridge, Massachusetts. The company develops the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates multiple unit processes (activation, transduction, expansion, and harvest) into a single core consumable, supported by modular Automated Manufacturing Units (AMUs) designed for parallel, scale-out production. The platform also includes the Solupore® Integrated Research Tool (RT) for discovery and translational workflows and the SoluPrime Knock-In Transfection Enhancer as a consumable add-on, with a Drug Master File filed with the FDA and 21 CFR Part 11 electronic batch record compliance for GMP manufacturing customers.

Avectas targets three primary customer segments: enterprise biopharma and cell therapy developers, CDMOs (notably through a strategic channel partnership with CCRM and its subsidiary OmniaBio), and academic and translational research institutions. Its value proposition centers on reducing cell therapy manufacturing economics — claiming 75% facility cost reduction, 600% throughput increase (~350 vs ~50 batches per year), and up to 25% cost-of-goods reduction versus conventional integrated platforms — while improving batch reliability through closed-system automation, inline pH/DO/CO2 sensors, and barcoded chain-of-identity. The company supports non-viral editing workflows including mRNA, CRISPR, and HDR, and is documented to produce >2.5 billion viable cells and >1 billion CD19-CAR+ cells in a 7-day process from 150M CD3+ starting cells.

The company generates revenue through a mix of capital equipment sales (AMUs), recurring consumables (single-use kits for each manufactured batch), and professional services for technology transfer from research use to GMP manufacturing, sold via direct enterprise sales and channel partnerships on multi-year B2B contracts. Total disclosed funding across four rounds between 2018 and 2021 is approximately $38.9M, the largest being a $20M round in April 2020. The scientific advisory board includes prominent figures in cell therapy (Prof. Bruce L. Levine of UPenn, Prof. Mark Lowdell, Prof. Evren Alici), and the company is actively pursuing both US market expansion and CDMO-led distribution channels to scale commercial adoption.

Short descriptiontext

Avectas develops the Solupore® Integrated platform, a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single consumable. It serves biopharma companies, CDMOs, and academic research institutions worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, automated bioprocessing equipment, non-viral cell engineering, CAR-T manufacturing platform, single-use bioreactors
Industry1 code
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cell Therapy Manufacturing Equipment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Solupore Integrated Consumables
TypeHardware Sales
Description

Sale of single-use consumable kits for cell therapy manufacturing. The platform is consumable-based, requiring ongoing purchase of consumables for each batch of cell therapy produced.

avectas.com
2Automated Manufacturing Units (AMUs)
TypeHardware Sales
Description

Sale of automated manufacturing unit equipment for modular scale-out. Equipment enables parallel processing and centralized control with electronic run records.

avectas.com
3GMP Manufacturing Platform
TypeProfessional Services
Description

Technology transfer and GMP manufacturing support for transitioning from research use (RUO) to full GMP manufacturing.

avectas.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise B2B pricing for GMP-compatible manufacturing platform
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; direct sales engagement required for quotes. Platform includes both capital equipment (AMUs) and recurring consumables.

avectas.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Solupore Integrated
Description

Automated, integrated and scalable cell therapy manufacturing platform that consolidates activation, transduction, expansion, and harvest into a single closed consumable system.

avectas.com
+2 more records
Core offering1 text field

Avectas develops and sells the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single core consumable supported by modular Automated Manufacturing Units (AMUs). The company supplies both a GMP-grade manufacturing system for clinical/commercial cell therapy production and a research-use Solupore Integrated Research Tool (RT), along with the SoluPrime Knock-In Transfection Enhancer reagent, targeting biopharma developers, CDMOs, and academic research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Facility cost reduction of 75% vs other integrated platforms
+4 more records
Product overview1 text field

Avectas offers Solupore® Integrated as its core automated manufacturing platform for cell and gene therapies, consolidating multiple unit processes (activation, transduction, expansion, and harvest) into a single closed consumable. The platform is available in two variants: the GMP-grade Solupore® Integrated for clinical and commercial manufacturing, and the Solupore® Integrated Research Tool (RT) for discovery and translational workflows. SoluPrime Knock-In Transfection Enhancer is an add-on reagent that primes cells for improved knock-in efficiency when combined with electroporation delivery, extending the platform's genome editing capabilities.

Product and service1 record
1Solupore® Integrated
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

CCRM and its CDMO subsidiary OmniaBio partnered with Avectas to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform. The evaluation aims to complement CCRM's global network of advanced therapy hubs and improve automation, scalability and manufacturing efficiency. The partnership coincides with plans to establish CCRM Ireland, supported by a government MOU between Ireland and Canada for expanded life science collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

CDMO subsidiary of CCRM partnering to evaluate Avectas' Solupore Integrated platform for cell therapy manufacturing, with focus on automation and scalability improvements.

Strategic tierKeyTypeTechnology or Integration
Description

Collaboration study demonstrating successful reprogramming of blood cell types using srRNA to produce functional iPSCs. First study to successfully demonstrate reprogramming using this method.

4Sony Biotechnology
Strategic tierKeyTypeTechnology or Integration
Description

Application note collaboration demonstrating that Solupore Integrated transfected cells isolated using Sony's CGX10 yield highly cytotoxic CAR-T cells. Joint webinar hosted October 28, 2025.

avectas.com
Strategic tierSupportingTypeTechnology or Integration
Description

Application note on Solupore Integrated knock-in using GenScript GenExact single-stranded DNA, demonstrating integration capabilities.

Strategic tierSupportingTypeTechnology or Integration
Description

Application note demonstrating that Solupore Integrated provides superior cellular avidity, essential for optimizing cell therapy processes.

Strategic tierSupportingTypeTechnology or Integration
Description

Multiple application notes demonstrating Solupore Integrated performance in Scaleready platforms, including enhanced stem cell memory and cytotoxic function in engineered T cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Privately held German life-science tools company whose Prodigy platform is the most established integrated, automated cell therapy manufacturing system. Direct competitor to Solupore Integrated for autologous CAR-T and other engineered cell therapy workflows at biopharma and CDMO customers.

TypeBroad incumbent
Description

Global CDMO and bioprocessing incumbent offering the Cocoon platform for automated, closed cell therapy manufacturing alongside a large contract manufacturing footprint. Competes with Avectas both as a platform vendor and as a service provider to the same biopharma customers.

TypeDirect peer
Description

US-listed company whose Flow Electroporation technology is a leading non-viral cell engineering platform used in clinical and commercial cell therapy manufacturing. Directly comparable core delivery modality to Solupore's non-viral mRNA/CRISPR/HDR workflows.

TypeDirect peer
Description

Well-funded startup commercializing the Cell Shuttle, a high-throughput automated cell therapy manufacturing platform positioned for both autologous and allogeneic workflows. Closest emerging-stage direct competitor to Solupore Integrated.

TypeDirect peer
Description

UK/US company developing an automated, closed cell and gene therapy manufacturing platform (Iro) targeted at cell therapy developers and CDMOs. Directly comparable go-to-market and product positioning to Avectas.

TypeBroad incumbent
Description

Large life-science tools and bioprocessing supplier with a broad Cell Therapy Systems (CTS) portfolio of instruments, consumables, and reagents used in cell therapy manufacturing. Counts as a partner (collaboration study) and an incumbent competitor to Avectas in the same customer workflows.

TypeBroad incumbent
Description

Global bioprocessing supplier (Danaher) offering instruments, consumables, and automation solutions across cell therapy and gene therapy manufacturing. Competes with Avectas as a broad incumbent in the same cell therapy manufacturing tool stack.

TypeEmerging player
Description

Early-stage company applying robotic automation to cell therapy manufacturing with a focus on modular, scalable production. Less mature and capital-light versus Avectas but overlapping product thesis and target customers.

TypeBroad incumbent
Description

Division of Terumo that provides cell processing systems, including the FINIA cell processing platform, used in cell and gene therapy manufacturing. Overlaps with Avectas in cell processing and is an established incumbent in apheresis/cell collection workflows.

TypeOthers
Description

Cell and gene therapy manufacturing solutions provider (a GPG/CTC joint venture) offering the G-Rex bioreactor platform and process development support. Existing Avectas partner for joint application notes, but adjacent (reagents/process platform) rather than direct head-to-head competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avectas

Cell Therapy Manufacturing Equipmentavectas.com

Avectas develops the Solupore® Integrated platform, a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single consumable. It serves biopharma companies, CDMOs, and academic research institutions worldwide.

What Avectas does

Avectas is a privately held Irish cell engineering technology company headquartered in Maynooth, Ireland, with an additional R&D facility in Dublin and a North American commercial office in Cambridge, Massachusetts. The company develops the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates multiple unit processes (activation, transduction, expansion, and harvest) into a single core consumable, supported by modular Automated Manufacturing Units (AMUs) designed for parallel, scale-out production. The platform also includes the Solupore® Integrated Research Tool (RT) for discovery and translational workflows and the SoluPrime Knock-In Transfection Enhancer as a consumable add-on, with a Drug Master File filed with the FDA and 21 CFR Part 11 electronic batch record compliance for GMP manufacturing customers.

Avectas targets three primary customer segments: enterprise biopharma and cell therapy developers, CDMOs (notably through a strategic channel partnership with CCRM and its subsidiary OmniaBio), and academic and translational research institutions. Its value proposition centers on reducing cell therapy manufacturing economics — claiming 75% facility cost reduction, 600% throughput increase (~350 vs ~50 batches per year), and up to 25% cost-of-goods reduction versus conventional integrated platforms — while improving batch reliability through closed-system automation, inline pH/DO/CO2 sensors, and barcoded chain-of-identity. The company supports non-viral editing workflows including mRNA, CRISPR, and HDR, and is documented to produce >2.5 billion viable cells and >1 billion CD19-CAR+ cells in a 7-day process from 150M CD3+ starting cells.

The company generates revenue through a mix of capital equipment sales (AMUs), recurring consumables (single-use kits for each manufactured batch), and professional services for technology transfer from research use to GMP manufacturing, sold via direct enterprise sales and channel partnerships on multi-year B2B contracts. Total disclosed funding across four rounds between 2018 and 2021 is approximately $38.9M, the largest being a $20M round in April 2020. The scientific advisory board includes prominent figures in cell therapy (Prof. Bruce L. Levine of UPenn, Prof. Mark Lowdell, Prof. Evren Alici), and the company is actively pursuing both US market expansion and CDMO-led distribution channels to scale commercial adoption.

Avectas firmographics

Firmographics
Name
Avectas
Legal name
Avectas
Website
https://avectas.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Avectas develops the Solupore® Integrated platform, a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single consumable. It serves biopharma companies, CDMOs, and academic research institutions worldwide.
Ownership category
akta.pro rank

Avectas industry classification

Industry
Product category
Cell Therapy Manufacturing Equipment
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy manufacturing
  • Automated bioprocessing equipment
  • Non-viral cell engineering
  • CAR-T manufacturing platform
  • Single-use bioreactors

Where Avectas is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices2 records

Markets served

Avectas business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Solupore Integrated Consumables: Sale of single-use consumable kits for cell therapy manufacturing. The platform is consumable-based, requiring ongoing purchase of consumables for each batch of cell therapy produced.
  2. Automated Manufacturing Units (AMUs): Sale of automated manufacturing unit equipment for modular scale-out. Equipment enables parallel processing and centralized control with electronic run records.
  3. GMP Manufacturing Platform: Technology transfer and GMP manufacturing support for transitioning from research use (RUO) to full GMP manufacturing.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise B2B pricing for GMP-compatible manufacturing platform

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Avectas product offering

Product offering

Core offering

Avectas develops and sells the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single core consumable supported by modular Automated Manufacturing Units (AMUs). The company supplies both a GMP-grade manufacturing system for clinical/commercial cell therapy production and a research-use Solupore Integrated Research Tool (RT), along with the SoluPrime Knock-In Transfection Enhancer reagent, targeting biopharma developers, CDMOs, and academic research institutions.

Product overview

Avectas offers Solupore® Integrated as its core automated manufacturing platform for cell and gene therapies, consolidating multiple unit processes (activation, transduction, expansion, and harvest) into a single closed consumable. The platform is available in two variants: the GMP-grade Solupore® Integrated for clinical and commercial manufacturing, and the Solupore® Integrated Research Tool (RT) for discovery and translational workflows. SoluPrime Knock-In Transfection Enhancer is an add-on reagent that primes cells for improved knock-in efficiency when combined with electroporation delivery, extending the platform's genome editing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Solupore Integrated: Automated, integrated and scalable cell therapy manufacturing platform that consolidates activation, transduction, expansion, and harvest into a single closed consumable system.
  • Solupore Integrated Research Tool (RT)
  • SoluPrime Knock-In Transfection Enhancer

Products and services

  • Solupore® Integrated

Quantifiable outcome

  • Facility cost reduction of 75% vs other integrated platforms
  • +4 more outcomes

Companies that use Avectas

Customer profile

Segments3 records

Ideal customer profiles3 records

Avectas technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Avectas partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, key and supporting.

  • CCRMcoreStrategic or Co-development Partner · 1 June 2026CCRM and its CDMO subsidiary OmniaBio partnered with Avectas to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform. The evaluation aims to complement CCRM's global network of advanced therapy hubs and improve automation, scalability and manufacturing efficiency. The partnership coincides with plans to establish CCRM Ireland, supported by a government MOU between Ireland and Canada for expanded life science collaboration.
  • OmniaBiocoreStrategic or Co-development Partner · 1 June 2026CDMO subsidiary of CCRM partnering to evaluate Avectas' Solupore Integrated platform for cell therapy manufacturing, with focus on automation and scalability improvements.
  • Thermo Fisher ScientifickeyTechnology or IntegrationCollaboration study demonstrating successful reprogramming of blood cell types using srRNA to produce functional iPSCs. First study to successfully demonstrate reprogramming using this method.
  • Sony BiotechnologykeyTechnology or IntegrationApplication note collaboration demonstrating that Solupore Integrated transfected cells isolated using Sony's CGX10 yield highly cytotoxic CAR-T cells. Joint webinar hosted October 28, 2025.
  • GenScriptsupportingTechnology or IntegrationApplication note on Solupore Integrated knock-in using GenScript GenExact single-stranded DNA, demonstrating integration capabilities.
  • LumickssupportingTechnology or IntegrationApplication note demonstrating that Solupore Integrated provides superior cellular avidity, essential for optimizing cell therapy processes.
  • ScalereadysupportingTechnology or IntegrationMultiple application notes demonstrating Solupore Integrated performance in Scaleready platforms, including enhanced stem cell memory and cytotoxic function in engineered T cells.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Avectas competitors and assessment

Company assessment

Direct peers

  • Miltenyi Biotec: Privately held German life-science tools company whose Prodigy platform is the most established integrated, automated cell therapy manufacturing system. Direct competitor to Solupore Integrated for autologous CAR-T and other engineered cell therapy workflows at biopharma and CDMO customers.
  • MaxCyte: US-listed company whose Flow Electroporation technology is a leading non-viral cell engineering platform used in clinical and commercial cell therapy manufacturing. Directly comparable core delivery modality to Solupore's non-viral mRNA/CRISPR/HDR workflows.
  • Cellares: Well-funded startup commercializing the Cell Shuttle, a high-throughput automated cell therapy manufacturing platform positioned for both autologous and allogeneic workflows. Closest emerging-stage direct competitor to Solupore Integrated.
  • Ori Biotech: UK/US company developing an automated, closed cell and gene therapy manufacturing platform (Iro) targeted at cell therapy developers and CDMOs. Directly comparable go-to-market and product positioning to Avectas.

Broad incumbents

  • Lonza: Global CDMO and bioprocessing incumbent offering the Cocoon platform for automated, closed cell therapy manufacturing alongside a large contract manufacturing footprint. Competes with Avectas both as a platform vendor and as a service provider to the same biopharma customers.
  • Thermo Fisher Scientific: Large life-science tools and bioprocessing supplier with a broad Cell Therapy Systems (CTS) portfolio of instruments, consumables, and reagents used in cell therapy manufacturing. Counts as a partner (collaboration study) and an incumbent competitor to Avectas in the same customer workflows.
  • Cytiva: Global bioprocessing supplier (Danaher) offering instruments, consumables, and automation solutions across cell therapy and gene therapy manufacturing. Competes with Avectas as a broad incumbent in the same cell therapy manufacturing tool stack.
  • Terumo BCT: Division of Terumo that provides cell processing systems, including the FINIA cell processing platform, used in cell and gene therapy manufacturing. Overlaps with Avectas in cell processing and is an established incumbent in apheresis/cell collection workflows.

Emerging players

  • Multiply Labs: Early-stage company applying robotic automation to cell therapy manufacturing with a focus on modular, scalable production. Less mature and capital-light versus Avectas but overlapping product thesis and target customers.

Others

  • ScaleReady: Cell and gene therapy manufacturing solutions provider (a GPG/CTC joint venture) offering the G-Rex bioreactor platform and process development support. Existing Avectas partner for joint application notes, but adjacent (reagents/process platform) rather than direct head-to-head competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Avectas social profiles

Digital presence

Avectas financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avectas leadership team

Management profile

Number of profiles

Profiles11 records

Avectas funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avectas M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avectas

What does Avectas do?

Avectas develops and sells the Solupore® Integrated platform — a closed, automated, sensor-enabled cell therapy manufacturing system that consolidates activation, transduction, expansion, and harvest into a single core consumable supported by modular Automated Manufacturing Units (AMUs). The company supplies both a GMP-grade manufacturing system for clinical/commercial cell therapy production and a research-use Solupore Integrated Research Tool (RT), along with the SoluPrime Knock-In Transfection Enhancer reagent, targeting biopharma developers, CDMOs, and academic research institutions.

Is Avectas a public or private company?

Avectas is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avectas founded?

Avectas was founded in 2011. It employs 11 to 50 people.

Where is Avectas based?

Avectas is headquartered in Dublin, Ireland, in the Europe region.

How does Avectas make money?

Three revenue lines are on record. Solupore Integrated Consumables are the primary driver. The others are automated Manufacturing Units (AMUs) and GMP Manufacturing Platform.

Who are Avectas's main competitors?

Direct peers on record are Miltenyi Biotec, MaxCyte, Cellares and Ori Biotech. Broad incumbents are Lonza, Thermo Fisher Scientific, Cytiva and Terumo BCT. Multiply Labs is listed as an emerging player. ScaleReady is listed as an others.

Does Avectas have an API?

No public API is recorded for Avectas.

What industry is Avectas in?

Avectas's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCell and gene therapy manufacturers turn to specialist automation partnersCell and gene therapy manufacturers are increasingly partnering with specialist automation companies to scale complex therapies, with collaborations focused on integrating robotics, digital systems, and advanced manufacturing platforms into production workflows. In June, Cellares partnered with TScan Therapeutics to evaluate automated clinical manufacturing for investigational T-cell therapy TSC-101 using Cellares' Cell Shuttle platform, building on an earlier collaboration with Autolus Therapeutics at its UK facility. Additional partnerships include Canada's Centre for Commercialization of Regenerative Medicine and OmniaBio with Ireland-based Avectas, and Fresenius Kabi with Cellular Origins, representing broader industry trends toward automation-enabled manufacturing models.GlobalDataCell and gene therapy manufacturers turn to specialist automation partners, says GlobalData – GlobalDataCell and gene therapy manufacturers are increasingly partnering with specialist automation companies to address scaling challenges for complex therapies, with recent collaborations including Cellares pairing with TScan Therapeutics for automated clinical manufacturing of T-cell therapy TSC-101. GlobalData's latest Bio/Pharmaceutical Outsourcing report highlights how developers and CDMOs are integrating robotics, digital systems, and AI into existing manufacturing workflows rather than building entirely new systems, as demonstrated by partnerships such as Fresenius Kabi with Cellular Origins and the Centre for Commercialization of Regenerative Medicine with Avectas. The FDA granted advanced manufacturing technology designation to Cellares's Cell Shuttle platform in 2025, reinforcing industry confidence in automated manufacturing solutions for late-stage clinical and commercial production.PR NewswireCCRM, OmniaBio and Avectas Partner to Improve Cell Therapy ManufacturingCCRM and its CDMO subsidiary OmniaBio announced an agreement with Avectas to evaluate Avectas' automated, integrated and scalable cell therapy manufacturing platform, aiming to complement CCRM's global network of advanced therapy hubs. The evaluation focuses on improving automation, scalability and manufacturing efficiency to address key challenges that limit patient access to cell and gene therapies. The partnership coincides with plans to establish CCRM Ireland, supported by a government MOU between Ireland and Canada for expanded life science collaboration.BioSpaceCCRM, OmniaBio and Avectas Partner to Improve Cell Therapy ManufacturingCCRM and its CDMO subsidiary OmniaBio announced an agreement with Avectas to evaluate its automated cell therapy manufacturing platform. The evaluation aims to complement CCRM's global hub network and OmniaBio's Intelligent Factory. CCRM's hubs are in Canada, Australia, and Nordic countries, with a proposed Irish hub.GlobeNewswireAvectas announces the appointment of Dr. Ann Brady as Chief Business OfficerAvectas appointed Dr. Ann Brady as Chief Business Officer, effective February 1, 2023, following the launch of its Solupore platform for cell therapies. Brady, a board member since 2016, brings 30 years of bio-pharma leadership experience. She will lead commercialization efforts, succeeding Daniel Castro.GlobeNewswireAvectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and FunctionalityAvectas launched the Solupore non-viral delivery system at Advanced Therapies Week in Miami Beach, enabling clinical manufacturing of gene-modified cell therapies with superior cell health and functionality. The system temporarily permeabilizes cell membranes to deliver mRNA, plasmids, RNP, or CRISPR/Cas9, and partners including Genscript, Inceptor Bio, and CCRM/Omnia bio have accessed it under an early access program.GlobeNewswireAvectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® TechnologyAvectas, CCRM, and OmniaBio expanded their collaboration to develop gene-edited induced pluripotent stem cells using Avectas' SOLUPORE non-viral cell engineering platform. The partnership aims to overcome current delivery limitations and accelerate the availability of edited iPSC banks for allogeneic cell therapies. OmniaBio's new manufacturing site will open in 2024.PR NewswireInceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid TumorsInceptor Bio and Avectas announced a collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for solid tumors. Under the agreement, Inceptor Bio will utilize Avectas' non-viral SOLUPORE® technology as an alternative to electroporation for engineering T cells, with the goal of producing healthier T cell products with improved functionality and durability in the tumor microenvironment. The partnership combines Avectas' cell engineering platform with Inceptor Bio's CAR-T, CAR-M, and CAR-NK cell therapy platforms to address limitations in current delivery modalities for complex gene editing.PR NewswireAvectas Announces New Chief Technology OfficerAvectas, a Dublin-based cell engineering technology business, announced the appointment of Dr Justin McCue as its new Chief Technology Officer, with Dr McCue to be based in Boston and lead the company's technological and scientific strategy for commercializing its SOLUPORE® platform. Dr McCue joins from Repertoire Immune Medicines where he served as Vice President of Technical Operations, and brings over 15 years of industry experience including prior roles at Juno/Celgene and Biogen. The article notes growing demand for novel cell transfection technologies to enable next-generation cell therapies.PR NewswireAvectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy appIrish cell engineering company Avectas announced publication of research on its SOLUPORE® non-viral delivery system in the journal Cytotherapy, demonstrating efficient engineering of primary human T cells for cell therapy applications using mRNA and CRISPR CAS9 RNP cargos while maintaining high cell viability. The study showed that CAR T cells engineered with the SOLUPORE® system exhibited high cytotoxicity against target cancer cells both in vitro and in vivo, with minimal gene expression changes compared to electroporation. Avectas CEO Dr Michael Maguire highlighted the published evidence as further validation of the platform's ability to preserve cellular functionality essential for cell therapies.